Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial to Compare the Efficacy and Safety of F-627 and GRAN in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia

Next Previous
Trial Profile

A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial to Compare the Efficacy and Safety of F-627 and GRAN in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efbemalenograstim alfa (Primary) ; Filgrastim
  • Indications Chemotherapy-induced damage; Neutropenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Evive Biotech; Generon (Shanghai) Corporation

Most Recent Events

  • 13 Sep 2024 Results assessing the efficacy and safety of F-627, also known as efbemalenograstim alfa (Ryzneuta R) in reducing neutropenia compared with filgrastim (GRAN R) were published in the BMC Cancer.
  • 27 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top